The pharmacology of the cannabinoid system—a question of efficacy and selectivity

Molecular Neurobiology

Volumn 36, Issue 1, 2007, Pages 15-25

  Fowler, Christopher J ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

2 Arachidonoylglycerol; Anandamide; Cannabinoid receptor; Fatty acid amide hydrolase; Monoacylglycerol lipase; Non steroidal anti inflammatory drugs

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 1 OXO 1[5 (2 PYRIDYL) 2 YL] 7 PHENYLHEPTANE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 [4 (1,1 DIMETHYLHEPTYL) 2,6 DIMETHOXYPHENYL] 6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YLMETHANOL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; 5 BIPHENYL 4 YLMETHYLTETRAZOLE 1 CARBOXYLIC ACID DIMETHYLAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; CANNABINOID; CANNABINOID 1 RECEPTOR; CAPSAZEPINE; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DESACETYLLEVANANTRADOL; DEXANABINOL; ENDOCANNABINOID; GW 405833; LY 2183240; METHANANDAMIDE; N (3 FURYLMETHYL)ARACHIDONAMIDE; N (4 HYDROXY 2 METHYLPHENYL)ARACHIDONAMIDE; N (4 HYDROXYPHENYL)ARACHIDONAMIDE; N OLEOYLETHANOLAMINE; N [1 4 HYDROXYBENZYL 2 HYDROXYETHYL] 9 OCTADECEN AMIDE; O 3640; O 3841; OCTADEC 9 ENOIC ACID 1 (FLUORO METHYL PHOSPHORYLOXYMETHYL) PROPYLESTER; OCTADEC 9 ENOIC ACID 1 METHOXYMETHYL 2 (FLUORO METHYL PHOSPHINOYLOXY) ETHYLESTER; OL 135; OMDM 2; PALMIDROL; RIMONABANT; UNCLASSIFIED DRUG; UNINDEXED DRUG; URB 602; [1,1' BIPHENYL 3 YL] CARBAMIC ACID CYCLOHEXYL ESTER; CANNABINOID RECEPTOR; LIGAND; PROSTAGLANDIN SYNTHASE;

CONFERENCE PAPER; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG SELECTIVITY; DRUG TARGETING; NONHUMAN; ANIMAL; HUMAN; METABOLISM; REVIEW; TREATMENT OUTCOME;

ANIMALS; CANNABINOIDS; HUMANS; LIGANDS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RECEPTORS, CANNABINOID; TREATMENT OUTCOME;

EID: 38449109538     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-007-0001-6     Document Type: Article

References (137)

1. Zias J, Stark H, Seligman J, Levy R, Werker E, Breuer A, Mechoulam R (1993) Early medical use of cannabis. Nature 363:215
2. Gaoni Y, Mechoulam R (1964) Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 86:1646-1647
3. Di Marzo V, Bifulco M, De Petrocellis L (2004) The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 3:771-784
4. Jonsson K-O, Holt S, Fowler CJ (2006) The endocannabinoid system: current pharmacological research and therapeutic possibilities. Basic Clin Pharmacol Toxicol 98:124-134
5. Fowler CJ (2005) Pharmacological properties and therapeutic possibilities for drugs acting upon endocannabinoid receptors. Curr Drug Targets CNS Neurol Disord 4:685-696
6. Mackie K (2006) Cannabinoid receptors as therapeutic targets. Annu Rev Pharmacol Toxicol 46:101-122
7. Begg M, Pacher P, Bátkai S, Osei-Hyiaman D, Offertáler L, Mo FM, Liu J, Kunos G (2005) Evidence for novel cannabinoid receptors. Pharmacol Ther 106:133-145
8. Baker D, Pryce G, Davies WL, Hiley CR (2006) In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol Sci 27:1-4
9. Barann M, Molderings G, Brüss M, Bönisch H, Urban BW, Göthert M (2002) Direct inhibition by cannabinoids of human 5-HT3A receptors: probable involvement of an allosteric modulatory site. Br J Pharmacol 137:589-596
10. Zygmunt PM, Petersson J, Andersson DA, Chuang H-h, Sørgård M, Di Marzo V, Julius D, Högestätt ED (1999) Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400:452-457
11. Walton RP, Martin LF, Keller JH (1938) The relative activity of various purified products obtained from American grown hashish. J Pharmacol Exp Ther 62:239-251
12. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG (2002) International union of pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54:161-202
13. Salo OMH, Savinainen JR, Parkkari T, Nevalainen T, Lahtela-Kakkonen ML, Gynther J, Laitinen JT, Järvinen T, Poso A (2006) 3D-QSAR studies on cannabinoid CB1 receptor agonists: G-protein activation as biological data. J Med Chem 49:554-566
14. Martin BR, Wiley JL, Beletskaya I, Sim-Selley LJ, Smith FL, Dewey WL, Cottney J, Adams J, Baker J, Hill D, Saha B, Zerkowski J, Mahadevan A, Razdan RK (2006) Pharmacological characterization of novel water-soluble cannabinoids. J Pharmacol Exp Ther 318:1230-1239
15. Lange JHM, Kruse CG (2004) Recent advances in CB1 cannabinoid receptor antagonists. Curr Opin Drug Discov Dev 7:498-506
16. Lambert DM, Fowler CJ (2005) The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. J Med Chem 48:5059-5087
17. Padgett LW (2005) Recent developments in cannabinoid ligands. Life Sci 77:1767-1798
18. Price MR, Baillie GL, Thomas A, Stevenson LA, Easson M, Goodwin R, McLean A, McIntosh L, Goodwin G, Walker G, Westwood P, Marrs J, Thomson F, Cowley P, Christopoulos A, Pertwee RG, Ross RA (2005) Allosteric modulation of the cannabinoid CB1 receptor. Mol Pharmacol 68:1484-1495
19. Pertwee RG (2001) Cannabinoid receptors and pain. Prog Neurobiol 63:569-611
20. Diana MA, Marty A (2004) Endocannabinoid-mediated shortterm synaptic plasticitiy: depolarization-induced suppression of inhibition (DSI) and depolarization-induced suppression of excitation (DSE). Br J Pharmacol 142:9-19
21. Park B, McPartland JM, Glass M (2004) Cannabis, cannabinoids and reproduction. Prostaglandins Leukot Essent Fat Acids 70:189-197
22. Croxford JL, Yamamura T (2005) Cannabinoids and the immune system: potential for the treatment of inflammatory diseases? J Neuroimmunol 166:3-18
23. De Vries TJ, Schoffelmeer ANM (2005) Cannabinoid CB1 receptors control conditioned drug seeking. Trends Pharmacol Sci 26:420-426
24. Kirkham TC (2005) Endocannabinoids in the regulation of appetite and body weight. Behav Pharmacol 16:297-313
25. Klein TW (2005) Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 5:400-411
26. Rang HP, Dale MM, Ritter JM, Moore PK (2003) Pharmacology, 5th edn. Churchill Livingstone, Edinburgh, pp 15-17
27. Pertwee RG (2005) Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci 76:1307-1324
28. Bouaboula M, Perrachon S, Milligan L, Canat X, Rinaldi-Carmona M, Portier M, Barth F, Calandra B, Pecceu F, Lupker J, Maffrand J-P, Le Fur G, Casellas P (1997) A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J Biol Chem 272:22330-22339
29. Vásquez C, Lewis DL (1999) The CB1 cannabinoid receptor can sequester G-proteins, making them unavailable to couple to other receptors. J Neurosci 19:9271-9280
30. Bouaboula M, Desnoyer N, Carayon P, Combes T, Casellas P (1999) Gi protein modulation induced by a selective inverse agonist for the peripheral cannabinoid receptor CB2: implication for intracellular signalization cross-regulation. Mol Pharmacol 55:473-480
31. Mukhopadhyay S, Howlett AC (2001) CB1 receptor-G protein association. Subtype selectivity is determined by distinct intracellular domains. Eur J Biochem 268:499-505
32. Mukhopadhyay S, Howlett AC (2005) Chemically distinct ligands promote differential CB1 cannabinoid receptor-Gi protein interactions. Mol Pharmacol 67:2016-2024
33. Bonhaus DW, Chang LK, Kwan J, Martin GR (1998) Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses. J Pharmacol Exp Ther 287:884-888
34. Shoemaker JL, Ruckle MB, Mayeux PR, Prather PL (2005) Agonist-directed trafficking of response by endocannabinoids acting at CB2 receptors. J Pharmacol Exp Ther 315:828-838
35. Yao BB, Mukherjee S, Fan Y, Garrison TR, Daza AV, Grayson GK, Hooker BA, Dart MJ, Sullivan JP, Meyer MD (2006) In vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB2 receptor? Br J Pharmacol 149:145-154
36. Kenakin T (2001) Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J 15:598-611
37. Shim J-Y, Howlett AC (2006) WIN55,212-2 docking to the CB1 cannabinoid receptor and multiple pathways for conformational induction. J Chem Inf Model 46:1286-1300
38. Shen C-P, Xiao JC, Armstrong H, Hagmann W, Fong TM (2006) F200A substitution in the third transmembrane helix of human cannabinoid CB1 receptor converts AM2233 from receptor agonist to inverse agonist. Eur J Pharmacol 531:41-46
39. Luk T, Jin W, Zvonok A, Lu D, Lin X-Z, Chavkin C, Makriyannis A, Mackie K (2004) Identification of a potent and highly efficacious, yet slowly desensitizing CB1 cannabinoid receptor agonist. Br J Pharmacol 142:495-500
40. Hilaret S, Bouaboula M, Carrière D, Le Fur G, Casellas P (2003) Hypersensitization of the orexin 1 receptor by the CB1 receptor. Evidence for cross-talk blocked by the specific CB1 antagonist, SR141716. J Biol Chem 278:23731-23737
41. Mackie K (2005) Cannabinoid receptor homo-and heterodimerization. Life Sci 77:1667-1673
42. Compton DR, Gold LH, Ward SJ, Balster RL, Martin BR (1992) Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from delta 9-tetrahydrocannabinol. J Pharmacol Exp Ther 263:1118-1126
43. Savinainen JR, Kokkola T, Salo OMH, Poso A, Järvinen T, Laitinen JT (2005) Identification of WIN55212-3 as a competitive neutral antagonist of the human cannabinoid CB2 receptor. Br J Pharmacol 145:636-645
44. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Bátkai S, Harvey-White J, Mackie K, Offertáler L, Wang L, Kunos G (2005) Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to dietinduced obesity. J Clin Invest 115:1298-1305
45. Kawamura Y, Fukaya M, Maejima T, Yoshida T, Miura E, Watanabe M, Ohno-Shosaku T, Kano M (2006) The CB1 cannabinoid receptor is the major cannabinoid receptor at excitatory presynaptic sites in the hippocampus and cerebellum. J Neurosci 26:2991-3001
46. Bloom AS, Edgemond WS, Moldvan JC (1997) Nonclassical and endogenous cannabinoids: effects on the ordering of brain membranes. Neurochem Res 22:563-568
47. Sagan S, Venance L, Torrens Y, Cordier J, Glowinski J, Giaume C (1999) Anandamide and WIN 55212-2 inhibit cyclic AMP formation through G-protein coupled receptors distinct from CB1 cannabinoid receptors in cultured astrocytes. Eur J Neurosci 11:691-699
48. Breivogel CS, Griffin G, Di Marzo V, Martin BR (2001) Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol 60:155-163
49. Hájos N, Ledent C, Freund TF (2001) Novel cannabinoidsensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience 106:1-4
50. Hoffman AF, Macgill AM, Smith D, Oz M, Lupica CR (2005) Species and strain differences in the expression of a novel glutamate-modulating cannabinoid receptor in the rodent hippocampus. Eur J Neurosci 22:2387-2391
51. Facchinetti F, Del Giuduce E, Furegato S, Passarotto M, Leon A (2003) Cannabinoids ablate release of TNFα in rat microglial cells stimulated with lypopolysaccharide. Glia 41:161-168
52. Nieri P, Greco R, Adinolfi B, Breschi MC, Martinotti E, Nannetti C, Podestà A (2003) CB1-and CB2-cannabinoid receptor-independent lipolysis induced by WIN 55,212-2 in male in rat adipocytes. Naunyn-Schmiedeberg’s Arch Pharmacol 368:352-359
53. Köfalvi A, Vizi ES, Ledent C, Sperlágh B (2003) Cannabinoids inhibit the release of [3H]glutamate from rodent hippocampal synaptosomes via a novel CB1 receptor-independent action. Eur J Neurosci 18:1973-1978
54. Köfalvi A, Rodrigues RJ, Ledent C, Mackie K, Vizi ES, Cunha RA, Sperlágh B (2005) Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis. J Neurosci 25:2874-2884
55. Nicholson RA, Liao C, Zheng J, David LS, Coyne L, Errington AC, Singh G, Lees G (2003) Sodium channel inhibition by anandamide and synthetic cannabimimetics in brain. Brain Res 978:194-204
56. Pistis M, Perra S, Pillolla G, Melis M, Gessa GL, Muntoni AL (2004) Cannabinoids modulate neuronal firing in the rat basolateral amygdala: evidence for CB1-and non-CB1-mediated actions. Neuropharmacology 46:115-125
57. Price TJ, Patwardhan A, Akopian AN, Hargreaves KM, Flores CM (2004) Cannabinoid receptor-independent actions of the aminoalkylindole WIN 55,212-2 on trigeminal sensory neurons. Br J Pharmacol 142:257-266
58. Steffens M, Feuerstein TJ (2004) Receptor-independent depression of DA and 5-HT uptake by cannabinoids in rat neocortex—involvement of Na+/K+-ATPase. Neurochem Int 44:529-538
59. Curran NM, Griffin BD, O’Toole D, Brady KJ, Fitzgerald SN, Moynagh PN (2005) The synthetic cannabinoid R(+) WIN55,212-2 inhibits the interleukin-1 signaling pathway in human astrocytes in a cannabinoid-receptor-independent manner. J Biol Chem 280:35797-35806
60. Nilsson O, Fowler CJ, Jacobsson SOP (2006) The cannabinoid agonist WIN 55,212-2 inhibits TNF-!-induced neutrophil transmigration across ECV304 cells. Eur J Pharmacol 547:165-173
61. Ahluwalia J, Urban L, Bevan S, Nagy I (2003) Anandamide regulates neuropeptide release from capsaicin-sensitive primary sensory neurons by activating both the cannabinoid 1 receptor and the vanilloid receptor 1 in vitro. Eur J Neurosci 17:2611-2618
62. Singh Tahim A, Sántha P, Nagy I (2005) Inflammatory mediators convert anandamide into a potent activator of the vanilloid type 1 transient receptor potential receptor in nociceptive primary sensory neurons. Neuroscience 136:539-548
63. Simon GM, Cravatt BF (2006) Endocannabinoid biosynthesis proceeding through glycerophospho-N-acyl ethanolamine and a role for α/ß-hydrolase 4 in this pathway. J Biol Chem 281: 26465-26472
64. Liu J, Wang L, Harvey-White J, Osei-Hyiaman D, Razdan R, Gong Q, Chan AC, Zhou Z, Huang BX, Kim H-Y, Kunos G (2006) A biosynthetic pathway for anandamide. Proc Natl Acad Sci USA 103:13345-13350
65. Melis M, Perra S, Muntoni AL, Pillolla G, Lutz B, Marsicano G, Di Marzo V, Gessa GL, Pistis M (2004) Prefrontal cortex stimulation induces 2-arachidonoyl-glycerol-mediated suppression of excitation in dopamine neurons. J Neurosci 24:10707-10715
66. Safo PK, Regehr WG (2005) Endocannabinoids control the induction of cerebellar LTD. Neuron 48:647-659
67. Bisogno T, Cascio MG, Saha B, Mahadevan A, Urbani P, Minassi A, Appendino G, Saturnino C, Martin B, Razdan R, Di Marzo V (2006) Development of the first potent and specific inhibitors of endocannabinoid biosynthesis. Biochim Biophys Acta 1761:205-212
68. Ligresti A, Morera E, Van Der Stelt MM, Monory K, Lutz B, Ortar G, Di Marzo V (2004) Further evidence for the existence of a specific process for the membrane transport of anandamide. Biochem J 380:265-272
69. Ronesi J, Gerdeman GL, Lovinger DM (2004) Disruption of endocannabinoid release and striatal long-term depression by postsynaptic blockade of endocannabinoid membrane transport. J Neurosci 24:1673-1679
70. Straiker A, Mackie K (2005) Depolarization-induced suppression of excitation in murine autaptic hippocampal neurones. J Physiol 569:501-517
71. Karlsson M, Påhlsson C, Fowler CJ (2004) Reversible, temperature-dependent, and AM404-inhibitable adsorption of anandamide to cell culture wells as a confounding factor in release experiments. Eur J Pharm Sci 22:181-189
72. Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz J-C, Piomelli D (1994) Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372:686-691
73. Hillard CJ, Edgemond WS, Jarrahian A, Campbell WB (1997) Accumulation of N-arachidonoylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion. J Neurochem 69:631-638
74. Kaczocha M, Hermann A, Glaser ST, Bojesen IN, Deutsch DG (2006) Anandamide uptake is consistent with rate-limited diffusion and is regulated by the degree of its hydrolysis by FAAH. J Biol Chem 281:9066-9075
75. Hermann A, Kaczocha M, Deutsch DG (2006) 2-Arachidonoylglycerol (2-AG) membrane transport: history and outlook. AAPS J 8:E409-E412
76. Fowler CJ (2006) The cannabinoid system and its pharmacological manipulation—a review, with emphasis upon the uptake and hydrolysis of anandamide. Fundam Clin Pharmacol 20:549-562
77. Beltramo M, Stella N, Calignano A, Lin SY, Makriyannis A, Piomelli D (1997) Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277:1094-1097
78. De Petrocellis L, Bisogno T, Davis JB, Pertwee RG, Di Marzo V (2000) Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Lett 483:52-56
79. López-Rodríguez ML, Viso A, Ortega-Gutiérrez S, Fowler CJ, Tiger G, de Lago E, Fernández-Ruiz J, Ramos JA (2003) Design, synthesis and biological evaluation of new endocannabinoid transporter inhibitors: comparison with effects upon fatty acid amidohydrolase. J Med Chem 46:1512-1522
80. Ortar G, Ligresti A, De Petrocellis L, Morera E, Di Marzo V (2003) Novel selective and metabolically stable inhibitors of anandamide cellular uptake. Biochem Pharmacol 65:1473-1481
81. Khanolkar AD, Abadji V, Lin S, Hill AG, Taha G, Abouzid K, Meng Z, Fan P, Makriyannis A (1996) Head group analogs of arachidonoylethanolamide, the endogenous cannabinoid ligand. J Med Chem 39:4515-4519
82. Zygmunt PM, Chuang H-h, Movahed P, Julius D, Högestätt ED (2000) The anandamide transport inhibitor AM404 activates vanilloid receptors. Eur J Pharmacol 396:39-42
83. Kelley BG, Thayer SA (2004) Anandamide transport inhibitor AM404 and structurally related compounds inhibit synaptic transmission between rat hippocampal neurons in culture independent of cannabinoid CB1 receptors. Eur J Pharmacol 496:33-39
84. Högestätt ED, Jönsson BAG, Ermund A, Andersson DA, Björk H, Alexander JP, Cravatt BF, Basbaum AI, Zygmunt PM (2005) Conversion of acetaminophen to the bioactive N-acyl phenolamine AM404 via fatty acid amide hydrolase-dependent arachidonic acid conjugation in the nervous system. J Biol Chem 280:31405-31412
85. 2+, questioning its selectivity as a pharmacological tool for investigating the anandamide transporter. J Pharmacol Toxicol Methods 45:195-198
86. De Lago E, Gustafsson SB, Fernández-Ruiz J, Nilsson J, Jacobsson SOP, Fowler CJ (2006) Acyl-based anandamide uptake inhibitors cause rapid toxicity to C6 glioma cells at pharmacologically relevant concentrations. J Neurochem 99:677-688
87. La Rana G, Russo R, Campolongo P, Bortolato M, Mangieri RA, Cuomo V, Iacono A, Raso GM, Meli R, Piomelli D, Calignano A (2006) Modulation of neuropathic and inflammatory pain by the endocannabinoid transport inhibitor AM404 [N-(4-hydroxyphenyl)-eicosa-5,8,11,14-tetraenamide]. J Pharmacol Exp Ther 317:1365-1371
88. Lastres-Becker I, de Miguel R, De Petrocellis L, Makriyannis A, Di Marzo V, Fernández-Ruiz J (2003) Compounds acting at the endocanabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington’s disease. J Neurochem 84:1097-1109
89. Fowler CJ, Holt S, Nilsson O, Jonsson K-O, Tiger G, Jacobsson SOP (2005) The endocannabinoid signaling system: pharmacological and therapeutic aspects. Pharmacol Biochem Behav 81:248-262
90. Moore SA, Nomikos GG, Dickason-Chesterfield AK, Schober DA, Schaus JM, Ying B-P, Xu T-CV, Phebus L, Simmons RMA, Li D, Iyengar S, Felder CC (2005) Identification of a highaffinity binding site involved in the transport of endocannabinoids. Proc Natl Acad Sci U S A 102:17852-17857
91. Dickason-Chesterfield AK, Kidd SR, Moore SA, Schaus JM, Liu B, Nomikos GG, Felder CC (2006) Pharmacological characterization of endocannabinoid transport and fatty acid amide hydrolase inhibitors. Cell Mol Neurobiol 26:407-423
92. Alexander JP, Cravatt BF (2006) The putative endocannabinoid transport blocker LY2183240 is a potent inhibitor of FAAH and several other brain serine hydrolases. J Am Chem Soc 128:9699-9704
93. Kathuria S, Gaetani S, Fegley D, Valiño F, Duranti A, Tontini A, Mor M, Tarzia G, La Rana G, Calignano A, Giustino A, Tattoli M, Palmery M, Cuomo V, Piomelli D (2003) Modulation of anxiety through blockade of anandamide hydrolysis. Nature Med 9:76-81
94. Lichtman AH, Leung D, Shelton CC, Saghatelian A, Hardouin C, Boger DL, Cravatt BF (2004) Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. J Pharmacol Exp Ther 311:441-448
95. Alexander JP, Cravatt BF (2005) Mechanisms of carbamate inactivation of FAAH: implications for the design of covalent inhibitors and in vivo functional probes for enzymes. Chem Biol 12:1179-1187
96. Fegley D, Kathuria S, Mercier R, Li C, Goutopoulos A, Makriyannis A, Piomelli D (2004) Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. Proc Natl Acad Sci USA 101:8756-8761
97. Quistad GB, Sparks SE, Segall Y, Nomura DK, Casida JE (2002) Selective inhibitors of fatty acid amide hydrolase relative to neuropathy target esterase and acetylcholinesterase: toxicological implications. Toxicol Appl Pharm 179:57-63
98. Paylor B, Holt S, Fowler CJ (2006) The potency of the fatty acid amide hydrolase inhibitor URB597 is dependent upon the assay pH. Pharmacol Res 54:481-485. Corrigendum published in Pharmacol Res 55 [2007] 80
99. Häbler C (1929) Über den K-und Ca-gehalt von eiter und exsudaten und seine beziehungen zum entzündungsschmerz. Klin Wochenschr 8:1569-1572
100. Boger DL, Miyauchi H, Du W, Hardouin C, Fecik RA, Cheng H, Hwang I, Hedrick MP, Leung D, Acevedo O, Guimarães CRW, Jorgensen WL, Cravatt BF (2005) Discovery of a potent, selective, and efficacious class of reversible !-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as analgesics. J Med Chem 48:1849-1856
101. Chang L, Luo L, Palmer JA, Sutton S, Wilson SJ, Barbier AJ, Breitenbucher JG, Chaplan SR, Webb M (2006) Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms. Br J Pharmacol 148:102-113
102. Clapper JR, Duranti A, Tontini A, Mor M, Tarzia G, Piomelli D (2006) The fatty-acid amide hydrolase inhibitor URB597 does not affect triacylglycerol hydrolysis in rat tissues. Pharmacol Res 54:341-344
103. Saghatelian A, McKinney MK, Bandell M, Patapoutian A, Cravatt BF (2006) A FAAH-regulated class of N-acyl taurines that activates TRP ion channels. Biochemistry 45:9008-9015
104. Farquhar-Smith W, Rice ASC (2003) A novel neuroimmune mechanism in cannabinoid-mediated attenuation of nerve growth factor-induced hyperalgesia. Anesthesiology 99:1391-1401
105. Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A, Piomelli D (2005) The nuclear receptor peroxisome proliferatoractivated receptor-! mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 67:15-19
106. Lo Verme J, Russo R, La Rana G, Fu J, Farthing JN, Mattace-Raso G, Meli R, Hohmann A, Calignano A, Piomelli D (2006) Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-α. J Pharmacol Exp Ther 319:1051-1061
107. Ahern GP (2003) Activation of TRPV1 by the satiety factor oleoylethanolamide. J Biol Chem 278:30429-30434
108. Fu J, Gaetani S, Oveisi F, Lo Verme J, Serrano A, Rodriguez de Fonseca F, Rosengarth A, Luecke H, Di Giacomo B, Tarzia G, Piomelli D (2003) Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-α. Nature 425:90-93
109. Overton HA, Babbs AJ, Doel SM, Fyfe MCT, Gardner LS, Griffin G, Jackson HC, Procter MJ, Rasamison CM, Tang-Christensen M, Widdowson PS, Williams GM, Reynet C (2006) Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab 3:167-175
110. Holt S, Comelli F, Costa B, Fowler CJ (2005) Inhibitors of fatty acid amide hydrolase reduce carrageenan-induced hind paw inflammation in pentobarbital-treated mice: comparison with indomethacin and possible involvement of cannabinoid receptors. Br J Pharmacol 146:467-476
111. Jayamanne A, Greenwood R, Mitchell VA, Aslan S, Piomelli D, Vaughan CW (2006) Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br J Pharmacol 147:281-288
112. Dinis P, Charrua A, Avelino A, Yaqoob M, Bevan S, Nagy I, Cruz F (2004) Anandamide-evoked activation of vanilloid receptor 1 contributes to the development of bladder hyperreflexia and nociceptive transmission to spinal dorsal horn neurons in cystitis. J Neurosci 24:11253-11263
113. Goparaju SK, Ueda N, Yamaguchi H, Yamamoto S (1998) Anandamide amidohydrolase reacting with 2-arachidonoylglycerol, another cannabinoid receptor ligand. FEBS Letts 422:69-73
114. Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, Kathuria S, Piomelli D (2002) Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci U S A 99:10819-10824
115. Nithipatikom K, Endsley MP, Isbell MA, Wheelock CE, Hammock BD, Campbell WB (2005) A new class of inhibitors of 2-arachidonoylglycerol hydrolysis and invasion of prostate cancer cells. Biochem Biophys Res Commun 332:1028-1033
116. Vandevoorde S, Saha B, Mahadevan A, Razdan RK, Pertwee RG, Martin BR, Fowler CJ (2005) Influence of the degree of unsaturation of the acyl side chain upon the interaction of analogues of 1-arachidonoylglycerol with monoacylglycerol lipase and fatty acid amide hydrolase. Biochem Biophys Res Commun 337:104-109
117. Saario SM, Salo OMH, Nevalainen T, Poso A, Laitinen JT, Järvinen T, Niemi R (2005) Characterization of the sulfhydrylsensitive site in the enzyme responsible for hydrolysis of 2-arachidonoyl-glycerol in rat cerebellar membranes. Chem Biol 12:649-656
118. Lu R, Hubbard JR, Martin BR, Kalimi MY (1993) Roles of sulfhydryl and disulfide groups in the binding of CP-55,940 to rat brain cannabinoid receptor. Mol Cell Biochem 121:119-126
119. Sasaki T, Chang MCJ (1997) N-Arachidonoylethanolamine (anandamide) formation from N-arachidonoylphosphatidolethanolamine in rat brain membranes. Life Sci 61:1803-1810
120. Schmid PC, Zuzarte-Augustin ML, Schmid HHO (1985) Properties of rat liver N-acylethanolamine amidohydrolase. J Biol Chem 260:14145-14149
121. Hohmann AG, Suplita RL, Bolton NM, Neely MH, Fegley D, Mangieri R, Krey JF, Walker JM, Holmes PV, Crystal JD, Duranti A, Tontini A, Mor M, Tarzia G, Piomelli D (2005) An endocannabinoid mechanism for stress-induced analgesia. Nature 435:1108-1112
122. Makara JK, Mor M, Fegley D, Szabó SI, Kathuria S, Astarita G, Duranti A, Tontini A, Tarzia G, Rivara S, Freund TF, Piomelli D (2005) Selective inhibition of 2-AG enhances endocannabinoid signaling in hippocampus. Nat Neurosci 8:1139-1141
123. Vandevoorde S, Jonsson K-O, Labar G, Persson E, Lambert DM, Fowler CJ (2007) Lack of selectivity of URB602 for 2-oleoylglycerol compared to anandamide hydrolysis in vitro. Br J Pharmacol 150:186-191
124. Saario SM, Palomäki V, Lehtonen M, Nevalainen T, Järvinen T, Laitinen JT (2006) URB754 has no effect on the hydrolysis or signalling capacity of 2-AG in the rat brain. Chem Biol 13:811-814
125. Kozak KR, Marnett LJ (2002) Oxidative metabolism of endocannabinoids. Prostaglandins Leukot Essent Fatty Acids 66:211-220
126. Fowler CJ, Tiger G, Stenström A (1997) Ibuprofen inhibits rat brain deamidation of anandamide at pharmacologically relevant concentrations. Mode of inhibition and structure-activity relationship. J Pharmacol Exp Ther 283:729-734
127. Fowler CJ, Holt S, Tiger G (2003) Acidic non-steroidal antiinflammatory drugs inhibit rat brain fatty acid amide hydrolase in a pH-dependent manner. J Enzym Inhib Med Chem 18:55-58
128. Gühring H, Hamza M, Sergejeva M, Ates M, Kotalla CE, Ledent C, Brune K (2002) A role for endocannabinoids in indomethacininduced spinal antinociception. Eur J Pharmacol 454:153-163
129. Ates M, Hamza M, Seidel K, Kotalla CE, Ledent C, Gühring H (2003) Intrathecally applied flurbiprofen produces an endocannabinoid-dependent antinociception in the rat formalin test. Eur J Neurosci 17:597-604
130. Guindon J, Beaulieu P (2006) Antihyperalgesic effects of local injections of anandamide, ibuprofen, rofecoxib ands their combinations in a model of neuropathic pain. Neuropharmacology 50:814-823
131. Guindon J, De Léan A, Beaulieu P (2006) Local interactions between anandamide, an endocannabinoid, and ibuprofen, a nonsteroidal anti-inflammatory drug, in acute and inflammatory pain. Pain 121:85-93
132. Guindon J, LoVerme J, De Léan A, Piomelli D, Beaulieu P (2006) Synergistic antinociceptive effects of anandamide, an endocannabinoid, and nonsteroidal anti-inflammatory drugs in peripheral tissue: a role for endogenous fatty-acid ethanolamides? Eur J Pharmacol 550:68-77
133. 1 receptors. Eur J Pharmacol 531:280-281
134. 2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice. Eur J Pharmacol 546:60-68
135. 2 receptor antagonist. Br J Pharmacol 146:917-926
136. Huang SM, Bisogno T, Petros TJ, Chang SY, Zavitsanos PA, Zipkin RE, Sivakumar R, Coop A, Maeda DY, De Petrocellis L, Burstein S, Di Marzo V, Walker JM (2001) Identification of a new class of molecules, the arachidonoyl amino acids, and characterization of one member that inhibits pain. J Biol Chem 276:42639-42644
137. Milman G, Maor Y, Abu-Lafi S, Horowitz M, Gallily R, Batkai S, Mo FM, Offertaler L, Pacher P, Kunos G, Mechoulam R (2006) N-arachidonoyl L-serine, an endocannabinoid-like brain constituent with vasodilatory properties. Proc Natl Acad Sci USA 103:2428-2433